NGL Fine Chem Ltd
Established in 1981, NGL Fine-Chem Limited manufacturers and markets APIs, Intermediates and Finished Dosage forms for human and animal pharmaceutical product. It caters to various Indian and global companies with high quality and reliable products. [1]
- Market Cap ₹ 768 Cr.
- Current Price ₹ 1,243
- High / Low ₹ 2,569 / 1,202
- Stock P/E 39.6
- Book Value ₹ 341
- Dividend Yield 0.14 %
- ROCE 34.7 %
- ROE 28.9 %
- Face Value ₹ 5.00
Pros
- Company has delivered good profit growth of 28.5% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 29.5%
Cons
- Earnings include an other income of Rs.13.0 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
35 | 36 | 56 | 79 | 88 | 96 | 100 | 114 | 153 | 152 | 258 | 319 | 276 | |
30 | 32 | 48 | 68 | 73 | 74 | 74 | 92 | 121 | 129 | 181 | 253 | 254 | |
Operating Profit | 5 | 4 | 8 | 11 | 15 | 22 | 25 | 22 | 32 | 23 | 77 | 66 | 22 |
OPM % | 14% | 11% | 14% | 14% | 17% | 23% | 26% | 19% | 21% | 15% | 30% | 21% | 8% |
0 | 0 | 0 | -1 | 2 | 0 | 1 | 3 | 4 | 1 | 9 | 13 | 13 | |
Interest | 1 | 1 | 1 | 2 | 2 | 2 | 1 | 2 | 3 | 3 | 2 | 2 | 1 |
Depreciation | 1 | 1 | 2 | 2 | 3 | 3 | 3 | 5 | 6 | 7 | 7 | 8 | 8 |
Profit before tax | 4 | 2 | 4 | 7 | 13 | 18 | 23 | 18 | 28 | 14 | 76 | 69 | 26 |
Tax % | 37% | 32% | 35% | 32% | 35% | 36% | 35% | 29% | 27% | 26% | 27% | 24% | |
Net Profit | 2 | 1 | 3 | 5 | 8 | 11 | 15 | 13 | 20 | 11 | 55 | 52 | 19 |
EPS in Rs | 3.92 | 1.70 | 4.71 | 7.33 | 13.48 | 18.45 | 24.10 | 20.38 | 32.58 | 17.16 | 89.79 | 84.57 | 31.44 |
Dividend Payout % | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | 5% | 10% | 2% | 2% |
Compounded Sales Growth | |
---|---|
10 Years: | 24% |
5 Years: | 26% |
3 Years: | 28% |
TTM: | -10% |
Compounded Profit Growth | |
---|---|
10 Years: | 48% |
5 Years: | 29% |
3 Years: | 37% |
TTM: | -67% |
Stock Price CAGR | |
---|---|
10 Years: | 55% |
5 Years: | 25% |
3 Years: | 73% |
1 Year: | -36% |
Return on Equity | |
---|---|
10 Years: | 27% |
5 Years: | 28% |
3 Years: | 30% |
Last Year: | 29% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Sep 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | |
Reserves | 13 | 14 | 17 | 21 | 30 | 41 | 56 | 69 | 89 | 98 | 152 | 203 | 208 |
6 | 10 | 13 | 17 | 13 | 14 | 23 | 27 | 27 | 28 | 16 | 30 | 27 | |
9 | 10 | 14 | 15 | 21 | 19 | 20 | 31 | 23 | 26 | 34 | 41 | 39 | |
Total Liabilities | 32 | 37 | 47 | 56 | 67 | 78 | 102 | 129 | 142 | 156 | 206 | 278 | 276 |
11 | 10 | 18 | 19 | 17 | 24 | 25 | 56 | 61 | 61 | 58 | 59 | 61 | |
CWIP | 1 | 5 | -0 | -0 | 1 | 2 | 16 | 3 | -0 | -0 | 1 | 6 | 15 |
Investments | 2 | 2 | 0 | 0 | 2 | 3 | 6 | 6 | 9 | 14 | 33 | 32 | 37 |
19 | 21 | 30 | 37 | 46 | 49 | 55 | 63 | 73 | 80 | 115 | 180 | 163 | |
Total Assets | 32 | 37 | 47 | 56 | 67 | 78 | 102 | 129 | 142 | 156 | 206 | 278 | 276 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
4 | 1 | -0 | -0 | 8 | 8 | 10 | 22 | 9 | 20 | 27 | 13 | |
-6 | -4 | -3 | -4 | -3 | -10 | -10 | -21 | -10 | -19 | -24 | -13 | |
1 | 3 | 4 | 3 | -4 | 2 | -0 | -0 | -0 | -1 | -1 | -1 | |
Net Cash Flow | -0 | -0 | 1 | -1 | 1 | 0 | -0 | 1 | -1 | -0 | 2 | -1 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 112 | 115 | 100 | 110 | 107 | 123 | 110 | 89 | 79 | 63 | 53 | 74 |
Inventory Days | 103 | 113 | 126 | 77 | 106 | 90 | 114 | 134 | 106 | 154 | 132 | 133 |
Days Payable | 158 | 156 | 148 | 105 | 150 | 122 | 139 | 187 | 92 | 114 | 94 | 84 |
Cash Conversion Cycle | 57 | 72 | 78 | 82 | 63 | 91 | 85 | 35 | 93 | 103 | 91 | 124 |
Working Capital Days | 80 | 81 | 88 | 88 | 77 | 96 | 85 | 54 | 107 | 98 | 78 | 116 |
ROCE % | 22% | 11% | 19% | 24% | 29% | 37% | 34% | 22% | 28% | 15% | 52% | 35% |
Documents
Announcements
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 15h
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 16 Mar
- Re-Submission Of Unaudited Financial Results For The Quarter And Nine Months Ended December 31, 2022 In Machine Readable Form. 1 Mar
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 25 Feb
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 25 Feb
Annual reports
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
Feb 2023TranscriptNotesPPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Jun 2021TranscriptNotesPPT
-
Jun 2021Transcript PPT
-
Nov 2020TranscriptPPT
-
Jul 2020TranscriptPPT
-
Dec 2019TranscriptPPT
Product Portfolio
Presently, Veterinary APIs is the main product of the company which account for 88% of its revenues, followed by Veterinary Formulations (5%), Human APIs (4%), & Others (3%). [1]
24 APIs (22 veterinary, 2 human), 4 intermediates, 10 finished dosage forms
Leadership in top 5 products – 50%+ market share. [2]